Next, we performed immunohistochemistry (IHC) staining on NSCLC patient samples to compare the levels of PRSS3, PAR2, and FRA1 between adjacent tissues (n = 30) and lung tumors (n = 30). This evidence concerns the gene PRSS3 and non-small cell lung carcinoma.